GPCR Structure Therapeutics Inc
Price (delayed)
$16.95
Market cap
$970.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.34
Enterprise value
$805.34M
We are a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Our differentiated
Highlights
GPCR's debt is down by 29% YoY and by 12% QoQ
The equity has surged by 91% year-on-year but it has declined by 3.6% since the previous quarter
GPCR's quick ratio is up by 30% year-on-year but it is down by 10% since the previous quarter
The net income has contracted by 37% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of GPCR
Market
Valuations
Earnings
Shares outstanding
57.29M
Market cap
$970.99M
Enterprise value
$805.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$158.23M
Net income
-$122.53M
EBIT
-$122.22M
EBITDA
-$119.62M
Free cash flow
-$117.93M
Per share
Balance sheet
Liquidity
EPS
-$2.34
EPS diluted
-$2.34
Free cash flow per share
-$2.24
Book value per share
$15.12
Revenue per share
$0
TBVPS
$17.18
Total assets
$903.33M
Total liabilities
$38.49M
Debt
$3.86M
Equity
$864.84M
Working capital
$855.19M
Debt to equity
0
Current ratio
24.74
Quick ratio
24.53
Net debt/EBITDA
1.38
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-15.1%
Return on equity
-15.7%
Return on invested capital
-21.1%
Return on capital employed
-14.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GPCR stock price
How has the Structure Therapeutics stock price performed over time
Intraday
7.35%
1 week
-15.25%
1 month
-28.63%
1 year
-57.11%
YTD
-37.5%
QTD
-2.08%
Financial performance
How have Structure Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$158.23M
Net income
-$122.53M
Gross margin
N/A
Net margin
N/A
GPCR's operating income has plunged by 54% YoY and by 11% from the previous quarter
The net income has contracted by 37% YoY and by 11% from the previous quarter
Growth
What is Structure Therapeutics's growth rate over time
Valuation
What is Structure Therapeutics stock price valuation
P/E
N/A
P/B
1.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GPCR's EPS is down by 7% QoQ but it is up by 3.7% YoY
The equity has surged by 91% year-on-year but it has declined by 3.6% since the previous quarter
GPCR's P/B is 63% less than its last 4 quarters average of 2.8
Efficiency
How efficient is Structure Therapeutics business performance
GPCR's ROIC has soared by 55% YoY and by 7% from the previous quarter
GPCR's return on equity has surged by 52% year-on-year and by 4.3% since the previous quarter
The ROA has soared by 50% year-on-year and by 3.8% since the previous quarter
Dividends
What is GPCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GPCR.
Financial health
How did Structure Therapeutics financials performed over time
Structure Therapeutics's total assets has surged by 87% YoY but it has decreased by 3.2% QoQ
Structure Therapeutics's total liabilities has increased by 32% YoY and by 6% from the previous quarter
GPCR's debt is 100% lower than its equity
The debt to equity has dropped by 100% year-on-year
The equity has surged by 91% year-on-year but it has declined by 3.6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.